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ABSTRACT 
Millions of people are affected by respiratory diseases, leading to a significant health burden 
globally.  Due to the current insufficient knowledge of the underlying mechanisms that lead to 
the development and progression of respiratory diseases, treatment options remain limited. 
To overcome this limitation and understand the associated molecular changes, non-invasive 
imaging techniques such as positron emission tomography (PET) and single photon emission 
computed tomography have been explored for biomarker development, with 18F-
fluorodeoxyglucose (18F-FDG) PET imaging being the most studied. The quantification of 
pulmonary molecular imaging data remains challenging due to variations in tissue, air, blood 
and water fractions within the lungs. The proportions of these components further differ 
depending on the lung disease. Therefore, different quantification approaches have been 
proposed to address these variabilities. However, no standardized approach has been 
developed to date. This article reviews the data evaluating 18F-FDG PET quantification 
approaches in lung diseases, focusing on methods to account for variations in lung 
components and the interpretation of the derived parameters. The diseases reviewed include 
acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) 
and interstitial lung disease such as idiopathic pulmonary fibrosis (IPF). Based on review of 
prior literature, ongoing research and discussions amongst the authors, suggested 
considerations are presented to assist with the interpretation of the derived parameters from 
these approaches and the design of future studies.  
 
Objectives: To raise the awareness of the issues when quantifying uptake of PET tracers in 
the lungs, focusing on 18F-FDG.  
 
1. Describe the methods that have been used to quantify 18F-FDG uptake in the lungs 
using dynamic PET. 
2. Discuss the interpretation of the outcomes from these methods. 
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3. Provide suggested considerations on quantification of 18F-FDG uptake in the lungs for 
future studies. 
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INTRODUCTION  
Motivation for developing PET lung imaging techniques 
Respiratory diseases are a significant global health burden that affects millions of people (1,2). 
However, treatment options remain limited because pathogenic mechanisms remain poorly 
understood. The clinical manifestations and severity of lung diseases vary significantly, and 
the number of clinical biomarkers available to identify aggressive disease phenotypes with 
accelerated progression is limited. Furthermore, 50% of drugs fail in Phase III trials due to lack 
of demonstrable efficacy, and respiratory drugs are often the most costly to develop. These 
facts highlight the need for quantitative biomarkers to select appropriate therapeutic targets 
and assess the efficacy of novel respiratory therapies (1,3,4).  
The United States Food and Drug Administration defines a biomarker as “a defined 
characteristic that is measured as an indicator of normal biological processes, pathogenic 
processes, or responses to an exposure or intervention, including therapeutic interventions” 
(5).  Traditional clinical measures, such as global lung function, reflect disease severity rather 
than disease activity. Since inflammation is commonly associated with respiratory diseases, 
robust molecular biomarkers of pulmonary inflammation could be applied (i) in early-phase 
clinical pharmacodynamic studies of anti-inflammatory therapies; (ii) as a complement to 
structural imaging and functional spirometry measures in phenotyping patients who may 
benefit from more intensive therapy or earlier lung transplant; and (iii) as a tool to improve our 
understanding of the pathogenic mechanisms of these complex lung diseases.  
Molecular imaging approaches such as positron emission tomography (PET) and single 
photon emission computed tomography could meet the need for non-invasive biomarkers of 
lung disease (6). Because inflammatory cell recruitment leads to increased glucose utilization 
in the lungs, 18F-FDG PET has been widely explored as a biomarker of pulmonary 
inflammation (7-11). However, standardized quantification approaches are lacking. To isolate 
the 18F-FDG uptake by parenchymal and immune/inflammatory cells, different methods have 
been proposed to account for regional variations in the fractions of air, blood, and water, which 
can vary dramatically with each lung disease. Accounting for these variations will apply equally 
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to new molecular imaging tracers that can measure the activity of specific aspects of lung 
inflammation or other processes such as fibrosis or endothelial cell activity, as recently 
reviewed (12,13). 
A primary goal for this field is to standardize these approaches for each lung condition. 
Variability in measured tracer uptake also arises from respiratory motion and differences in 
reconstruction approaches, among other factors, but these technical issues will be discussed 
only briefly. Quantification methods for 18F-FDG lung imaging will be reviewed as it is the most 
widely studied PET tracer to date and serves as a model for all PET and single photon 
emission computed tomography tracers used for lung imaging.  
 
Clinical applications investigated with 18F-FDG PET imaging 
Inflammation characterizes a number of lung diseases, including pneumonia, cystic 
fibrosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome 
(ARDS), asthma, and interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF), 
among others (7,8,10,11,14‐25). As ARDS, COPD, and IPF can cause significant variability in 
the amounts of air, blood, and water in the lungs (Fig. 1), we will focus our methodology 
discussion on these diseases. ARDS is characterized by persistent pulmonary neutrophilic 
inflammation, edema, and pulmonary hemorrhage. These can lead to signal from unbound 
18F-FDG in the increased blood and water fractions as well as specific trapping in neutrophils 
(26). In COPD, increased numbers of lung neutrophils and macrophages (1,27-30) would be 
expected to increase the 18F-FDG signal despite a reduction in measured 18F-FDG due to 
larger air fractions and reduced blood volumes as a result of emphysema (31). Finally, IPF is 
characterized by interstitial pneumonia along with fibrosis in a characteristic subpleural pattern 
of distribution, leading to reduced air, increased fibrosis, and alterations in blood volume 
depending on the stage of fibrosis (32). These differences in pathobiology highlight the need 
to account for the changes in the cellular and fluid composition in the lungs when interpreting 
any increased lung 18F-FDG uptake. Exacerbations also represent a confounding factor 
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leading to increased lung inflammation and 18F-FDG uptake; consequently, most studies have 
been performed in the clinically stable state. 
 
ANALYSIS METHODS AND THEIR APPLICATIONS IN LUNG DISEASES 
Quantification approaches for 18F-FDG 
Overview 
The 18F-FDG signal within each PET voxel or predefined region of interest (ROI) in the 
lungs represents the contribution of activity in parenchymal (i.e. alveolar), airway wall, vascular 
wall (e.g. endothelial cells) and immune cells (known collectively in this paper as 'lung cells'), 
as well as blood, and water (i.e. extracellular fluid). A number of factors can degrade the lung 
cells signal within each voxel, including normal respiratory motion and the presence of air that 
causes partial volume averaging within each voxel. Furthermore, the contribution of signal 
from compartments without specific binding, such as blood or water in the lungs, further 
reduces the signal specificity.  The ideal parameter for quantifying 18F-FDG lung uptake would 
reflect metabolic activity only from the cells thought to contribute to lung disease progression, 
namely the lung cells, to determine their pathogenic role. Therefore, investigations have tested 
different methods to account for the 18F-FDG signal in the blood and water and to remove the 
impact of air fraction so that an outcome measure specific to lung cells can be derived. While 
distinguishing the metabolism of specific cell types, such as parenchymal vs airway cells, 
would contribute significantly to mechanistic studies of lung disease, these quantification 
methods alone cannot provide such information. Consequently, finding ways to measure lung 
cell metabolism specifically will better characterize their role in promoting disease activity and 
progression. 
The methods used to quantify 18F-FDG uptake in human studies and that will be discussed 
in this review are summarized in Table 1. Compartmental modelling and Patlak graphical 
analysis have been used to quantify 18F-FDG uptake from dynamic images. The standardized 
uptake value (SUV), with or without dual time-point imaging, and tissue-to-blood ratio have 
been used for static images. Different approaches have been further applied to reduce the 
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contribution of background 18F-FDG signal from blood and water in the lungs as well as reduce 
partial volume averaging from air in the ROI. For example, kinetic modelling of dynamic PET 
data can determine the fractional blood volume, ẑᾥ. PET and CT images have been used to 
estimate the regional air fraction (ẑᾡ). Using ẑᾡ and ẑᾥ, the 18F-FDG uptake in everything that 
is not air and blood (i.e. lung cells and water), can be measured. These approaches are 
reviewed below, followed by a discussion of their specific applications in ARDS, COPD and 
IPF. 
 
Kinetic approaches 
The Sokoloff method for quantifying 18F-FDG uptake has served as the basis from which 
many of the currently used kinetic quantification approaches are derived (33,34). The method 
was originally developed for measuring brain glucose metabolism, but a key assumption was 
that the blood volume contribution was negligible relative to the brain parenchymal signal. This 
was a recognized limitation for applying the method in brain tumors, which have higher ẑᾥ 
than normal brain, necessitating the addition of a blood volume component to the model (35). 
With ẑᾥ estimated at approximately 0.16 in normal lungs, the blood component has a more 
substantial effect, both in terms of signal and fractional volume (Fig. 1). Therefore, including 
ẑᾥ in a lung compartment model is even more important. 
Furthermore, the lung contains air, which is not the case for other organs. Therefore, an 
equation (Eq. 1) that accounts for air and blood fractions separately from the other lung 
components (Fig. 2) has been published and applied in IPF and COPD (21,36): 
ɓɝሺɽሻ ൌ ɦɑɓɑሺɽሻ ൅ ɦɒɓɒሺɽሻ ൅ ሺᾈ െ ɦɒ െ ɦɑሻɓɤሺɽሻ  (Eq. 1) 
where, for a given ROI, ṥெሺݐሻ is the measured radioactivity concentration, ṥᾡሺݐሻ is the air 
concentration (which is negligible for intravenously administered tracers like 18F-FDG), ṥᾥሺݐሻ	is 
the blood concentration (derived from the dynamic images or blood samples), and ṥ்ሺݐሻ is the 
concentration in lung cells and water (i.e. everything that is not air or blood). ẑᾥ  can be 
estimated from the compartment model.  ẑᾡ can be determined from the attenuation-correction 
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CT after down-sampling to match the resolution of the PET image (37,38). Therefore, this 
model enables isolation of the signal from all non-air and non-blood lung components within 
the ROI (ṥ்ሺݐሻ ). However, when 1 െ ẑᾥ െ ẑᾡ  is less than 0.05 (i.e. in areas of severe 
emphysema), the accuracy of this correction should be treated with caution (21). 
The Patlak graphical analysis is derived from the general compartment model for tracers 
that are irreversibly trapped in the target tissue (39,40). This analysis provides two parameters: 
an estimate of the influx rate constant Ki, a measure of 18F-FDG metabolism, and the intercept, 
which approximates the distribution volume of all the components of the reversible 
compartment(s). This method is independent of the number of compartments. Intercept 
normalization of the Ki has been attempted to account for the impact of air on the measurement. 
However, from Eq. 1, it can be shown that the intercept-normalized Patlak Ki (KiN) is still 
influenced by both ẑᾡ and ẑᾥ (34).  
With these methods, after correcting for ẑᾡ and ẑᾥ, the estimated 18F-FDG uptake comes 
from the lung cells and water (i.e. everything that is not air or blood). In ILDs and COPD, this 
is sufficient as the water fraction is small. However, in conditions with increased edema, such 
as ARDS, the water fraction can be significant. Using independent measures of the tissue 
fraction, ẑᾥ, and wet-to-dry ratios (as a measure of water), the normalized Ki determined by 
the Sokoloff model or a modified four-compartment model that includes a compartment for 
nonspecific trapping has been used to isolate the lung cell metabolic activity (41-43). These 
studies confirm the importance of further evaluating modelling approaches that can account 
for the effects of air, blood and water together to measure the lung cell 18F-FDG signal 
specifically. 
 
Static image quantification approaches  
The standardised uptake value (SUV) is the concentration measured within a region or 
voxel normalised to the patient weight and the injected activity. This is the most common 
parameter measured clinically for PET due to its simplicity, despite its dependency on 
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metabolism in other organs, body mass and other confounding factors (44,45).  The SUV is 
also affected by air within ROIs. Normalizing it for the air fraction will likely improve its accuracy 
as a reflection of lung cell metabolic activity (38). Normalization for blood (such as the tissue-
to-blood ratio, as explored in a dog model of ARDS (46)) may further improve accuracy ẑᾥ; 
however, whether this approach is comparable to correcting for  ẑᾥ  as measured by kinetic 
analysis or other imaging (such as 15O-CO scans) remains to be seen. 
  
Other contributions to errors in 18F-FDG quantification in the lungs 
Reconstruction algorithms used to generate PET images can have a significant impact on 
quantification accuracy, including issues with non-linearity and under-convergence when 
using iterative algorithms (45). The majority of research in this area has focused on detecting 
lung cancers, which have high signal relative to the lungs. Therefore, further investigation is 
needed to optimize reconstruction performance for the diffusely distributed, relatively low 
count activity typically seen in the lungs. 
Accurately matching tissue densities between PET and CT images is also essential for 
accurate PET image attenuation correction and ẑᾡ correction. Gross spatial misregistration of 
the measured attenuation map and PET activity distribution, which frequently occurs at the 
diaphragm, is known to cause attenuation correction artifacts (47,48). Additionally, changes 
in lung density from normal respiration between the PET and CT acquisitions can lead to 
errors in attenuation and ẑᾡ  correction, introducing additional variability to serial 
measurements and limiting accurate assessment of the entire lung volume (49). Improved 
methods for measuring changes in lung density, as well as algorithms to reduce the impact of 
respiration (50,51) warrant further investigation to improve PET/CT quantification accuracy in 
lung disease.  
 
ARDS 
The Patlak graphical analysis and compartmental model for quantifying lung 18F-FDG 
uptake have been evaluated most extensively in animal and human models of ARDS 
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(41,46,52-57). In animal models of ARDS, the Patlak Ki correlated with 3H-deoxyglucose 
uptake in airway cells obtained by bronchoalveolar lavage (52), and Ki normalized for tissue 
fraction (determined independently by 13N-N2 scans) correlated with lung neutrophil numbers 
by histology (53). The Ki determined by the Sokoloff model and by a four-compartment model 
that includes a water compartment, when normalized for tissue fraction, blood fraction, and 
wet-to-dry ratios determined independently, further demonstrated regional differences in 
inflammation related to lung neutrophil numbers in correlating regions (42,43). In a healthy 
volunteer model of endotoxin-induced acute lung inflammation, both Ki and KiN increased, and 
both correlated weakly with neutrophil numbers (57). Other lung cells also likely contributed 
to increased 18F-FDG uptake after endotoxin instillation, as shown in mouse models (58,59). 
These data demonstrate that increased 18F-FDG uptake, quantified by both Ki and KiN, are 
associated with neutrophilic inflammatory responses in these models. 
Further validation with compartment modelling has also been performed in ARDS animal 
models. Independent measures of blood fraction and extravascular lung water obtained with 
15O-CO and 15O-H2O PET images correlated highly with three-compartmental model-derived 
estimates from the 18F-FDG data in a dog model (46). The compartment model estimate of 
the Patlak Ki also correlated highly with the Patlak-determined Ki. Finally, the addition of 
another compartment for extravascular lung water improved the model fits for estimating lung 
18F-FDG uptake in a sheep model, supporting the applicability of this approach in ARDS (41). 
Human studies in patients with ARDS have used the Patlak Ki without a correction for lung 
density or blood fraction but instead have simply compared the Ki in normal versus dense 
tissue separately across subjects (19,20). 
 
COPD 
Given the validation of CT for quantifying emphysema (60), 18F-FDG PET imaging holds 
great potential for providing additional inflammation-specific information. The KiN has been the 
primary metric for quantifying 18F-FDG uptake in COPD and asthma (10,17).  KiN correlates 
negatively with pulmonary function and positively with CT-determined emphysema severity 
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(17) (Fig. 3). KiN may also correlate with a chronic bronchitis phenotype (published in abstract 
form (61)), suggesting the clinical relevance of this parameter. However, KiN is not increased 
in subjects with stable asthma when compared to healthy volunteers (10). Furthermore, no 
difference in the whole lung Ki was noted between COPD patients and healthy volunteers after 
accounting for ẑᾡ and ẑᾥ  using compartmental modelling (published in abstract form (36)). 
The whole-lung SUV normalized for the CT-determined air fraction has also been explored in 
patients with COPD with emphysema but has not been compared with tissue-based or clinical 
outcome measures (39). Finally, both infections and allergens frequently trigger asthma and 
COPD exacerbations. KiN likely increases with both triggers, as has been shown in lung 
transplant recipients with infection (62) and in subjects with asthma after allergen challenge 
(8,24). Therefore, 18F-FDG PET scans will need to be obtained during periods of clinical 
stability to study the accuracy of different quantitative parameters for measuring lung disease-
specific inflammation. These studies together highlight the need to continue defining the 
relationship of the different 18F-FDG PET quantitative parameters to outcome measures to 
determine which metrics are the best surrogate measures of inflammation.   
 
Interstitial Lung Diseases/IPF 
Increased 18F-FDG uptake has been reported in the lungs of patients with idiopathic 
pulmonary fibrosis (IPF) using the maximum SUV with or without correction for the air fraction 
determined by CT (11,22,23,38). A study using dual time-point imaging further demonstrated 
that persistently increased 18F-FDG uptake predicted more rapid decline in lung function and 
higher mortality in patients with IPF (40). Glucose transporter-1 is expressed on erythrocytes 
and inflammatory cells in lung sections from patients with IPF, with erythrocyte but no 
inflammatory cell staining at sites of angiogenesis (63). Catabolism genes associated with 
increased glucose metabolism have increased expression by microarray analysis of human 
IPF samples (64). These data together support the potential clinical relevance of measuring 
18F-FDG uptake in this disease. However, a modelling analysis using Eq. 1 actually showed 
decreased 18F-FDG uptake in the fibrotic areas of the lung compared to areas that appeared 
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normal by CT when accounting for ẑᾡ and ẑᾥ (21) (Fig. 4). These findings still need to be 
compared to a similar analysis of healthy lungs, but they highlight how these modelling 
approaches can change the interpretation of 18F-FDG uptake in IPF. Additionally, improved 
registration methods are needed to accurately correct for attenuation changes in the periphery, 
where fibrosis typically occurs. Collectively, these results highlight the need for a gold standard 
comparator to validate the most relevant 8F-FDG parameters for IPF. 
 
ISSUES AND SUGGESTED CONSIDERATIONS 
The methodological issues discussed above highlight the need for further studies to 
determine and validate the most appropriate approaches for lung imaging. Based on 
discussions amongst the authors, the following summary statements were created to capture 
the key aspects that should be considered for future validation studies:  
1) PET measurements of 18F-FDG concentration in the lung are influenced by the relative 
volumes of lung cells, air, blood and water. 
2) It is essential to understand how the different methodologies account for the relative 
volumes of air, blood, and water when analyzing PET data to obtain measurements of 18F-
FDG concentration and/or kinetic parameters in the lungs.  
3) Relative air, blood and water volumes vary within the lung significantly among respiratory 
diseases and may depend on disease severity. Without correction, these differences can 
potentially cause significant variation in the quantified 18F-FDG PET signal.  
4) Although the KiN has been used as the endpoint in many previous publications on lung 18F-
FDG uptake, it does not adequately account for the impact of air and blood.  
5) Compartmental modelling is a standard methodology for PET image analysis that can be 
applied to lung 18F-FDG data. Using CT data to estimate the air fraction and a kinetic model 
to account for the blood fraction, it is possible to quantify the glucose metabolic rate for all 
remaining lung components (i.e. lung cells and water) with 18F-FDG. The compartment model 
may need modification to account for increased water (i.e. in ARDS). However, no complete 
modelling solution that includes air, blood and water fraction corrections has yet been tested. 
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CONCLUSION 
Investigating 18F-FDG uptake and kinetics in diffuse lung diseases is becoming more 
common for phenotyping, monitoring disease progression, and assessing the efficacy of novel 
targeted treatments. For this purpose, ideally 18F-FDG uptake is measured specifically in the 
lung cells that contribute to disease pathogenesis. However, regional variations in air, blood, 
and water fractions can lead to inaccurate estimates of the lung cell tracer concentration. 
Without accounting for these effects, PET quantification accuracy is compromised and could 
confound the correct interpretation of the PET parameters in the context of the known biology.  
To improve confidence in lung PET quantification, validation of methods to account for air, 
blood and water fractions using independent techniques would be desirable. For example, the 
data provided by serial 15O-CO, 15O-H2O, and dynamic 18F-FDG imaging in the same imaging 
session would provide increased confidence in the estimated blood and water volumes (37). 
Furthermore, the reproducibility and reliability of these outcome measures will need to be 
assessed in patients with a range of diffuse lung diseases and in healthy controls. Finally, 
comparison with clinical information, such as that from CT, lung tissue sampling, or pulmonary 
function testing, can provide additional context for correctly interpreting PET quantification 
parameters. These are recommended as examples of future work to promote the 
standardization of PET analysis methods for lung imaging.  
The conclusions laid out in this paper point to the need for a lung imaging collaboration 
that encourages data and protocol sharing. This will allow validation across the range of lung 
diseases to be studied, ultimately producing a standardized acquisition and processing 
methodology. Although not discussed as a focus of this review, these collaborative efforts will 
also facilitate the evaluation of the most appropriate reconstruction and motion correction 
algorithms and imaging protocols to optimize lung PET imaging. These efforts will ensure that 
accurate, reproducible and clinically interpretable images and estimated parameters can be 
produced together with the requisite clinical validation prior to use in clinical trials of 
established or novel therapies.   
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TABLE 1. Summary of human studies evaluating quantitative parameters for 18F-FDG uptake in the lungs. 
   
Cohort(s) Publication  
(Reference number) 
Number of subjects Parameters derived 
from PET imaging data 
Correlative data 
ARDS Bellani et al, 2009 (19) 10 Patlak Ki PFTs 
ARDS Bellani et al, 2011 (18) 13 Patlak Ki PFTs 
ARDS/HV Grecchi et al, 2015 (20) 11/5 CM Ki, Patlak Ki, SUV None 
ARDS model in HV Chen et al, 2006 (57) 18 Patlak Ki BAL neutrophil 3H-deoxyglucse 
uptake 
ARDS model in HV Chen et al, 2009 (56) 18 Patlak Ki BAL 
Asthma – BC Taylor et al, 1997 (24) 9 Patlak Ki BAL 
Asthma – BC Harris et al, 2011 (8) 6 Patlak Ki  BAL  
COPD/Asthma/HV Jones et al, 2003 (10) 6/6/5 Patlak KiN 11C-PBR28 uptake, PFT, Sputum  
COPD/HV/AATD-COPD Subramanian et al, 2012 
(17) 
10/10/10 
 
Patlak KiN PFTs 
COPD Torigian et al, 2013 (39) 49 AFC-SUV None 
Cystic Fibrosis/Control Labiris et al, 2003 (16) 8/3 Patlak Ki Sputum  
Cystic Fibrosis/HV Chen et al, 2006 (7)  20/7 Patlak Ki, KiN BAL and PFTs 
Cystic Fibrosis Klein et al, 2009 (25) 20 SUV PFTs, WBC, CRP 
Cystic Fibrosis/Control Amin et al, 2012 (15) 20/10 SUV PFTs, Sputum, CT metrics 
HV Lambrou et al, 2011 (38) 12 AFC-SUV  None 
ILDs including IPF Groves et al, 2009 (11) 18 IPF/18 other ILD SUV, TBR PFTs 
IPF Umeda, et al, 2015 (40) 50 Dual time point-SUV CT-derived fibrosis score, PFTs 
IPF  Holman et al, 2015 (21) 6 ABC-Patlak Ki,  
ABC-CM Ki 
None 
IPF Win et al, 2012 (22) 13 AFC-SUV None 
IPF/Controls Win et al, 2014 (23) 25/25 AFC-SUV None 
Pneumonia/Bronchiectasis Jones et al, 1997 (9) 5/5 KiN None 
AATD = Alpha-1 antitrypsin deficiency, ABC = Air and Blood Corrected, AFC = Air Fraction Corrected, ARDS = Acute respiratory distress syndrome, BAL = 
bronchoalveolar lavage, BC = Bronchoscopic challenge, CM = compartmental model, COPD = chronic obstructive pulmonary disease, CRP = C-reactive 
protein, CT = computed tomography, HV = healthy volunteer, IPF = idiopathic pulmonary fibrosis, KiN = Intercept-normalized Ki, PFTs = Pulmonary function 
tests,  SUV = standardized uptake value, TBR = Target-to-Background Ratio. 
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Figure 1. 
 
  
Figure 1. Variations in relative proportions of air, blood, lung tissue (parenchymal/airway 
and endothelial cells) and immune cells, and water by lung disease. The proportions of 
blood and tissue in brain are also shown for comparison.  
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Figure 2.  
 
 Figure 2. Schematic of the three compartment model describing the kinetics of the tracer in 
lung tissue (CT). CB is the concentration in blood, C1 is the concentration in the reversible 
compartment, C2 is the concentration in the irreversible (trapped) compartment, CT is the 
total tracer concentration in the tissue, CM is the measured concentration in the voxel or 
region, CA is the concentration in air, VA is the fractional air volume, VB is the fractional blood 
volume and Ki is the metabolic rate constant of 18F-FDG. The rate constants are represented 
here as K1, k2 and k3. A full derivation can be found in reference (34). 
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Figure 3.  
 
 
  
Figure 3. Increased intercept-normalized Patlak Ki in the upper lobes of the lungs of COPD 
patients correlates inversely with pulmonary function testing. (A) Three-dimensional imaging 
illustrating the predominantly apical distribution of pulmonary 18F-FDG uptake in a patient 
with chronic obstructive pulmonary disease (COPD). The maximum signal of this color 
spectrum is represented by white and the minimum signal by black. (B) Relationship 
between upper zone 18F-FDG uptake and FEV1 % predicted in the COPD group (n = 10). 
One-tailed P value shown. Reprinted with permission of the American Thoracic Society from 
reference (17). Copyright © 2016 American Thoracic Society. The American Journal of 
Respiratory and Critical Care Medicine is an official journal of the American Thoracic 
Society. 
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Figure 4.  
 
  
Figure 4. Patlak Ki parametric images from an IPF patient undergoing a dynamic 18F-FDG 
study. (A) CT image displaying regions of obvious fibrosis (white arrows) and a region of 
normal appearing tissue (black arrow). Patlak parametric images (B) before air and blood 
correction, (C) after air fraction correction, and (D) after air and blood fraction correction. All 
images have been normalized such that they can be shown on the same arbitrary gray 
scale. The images have been masked to show only the lung. Figure reprinted with 
permission from reference (21). 
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